Sogroya (somapacitan)
Additional monitoring
- Region
- 🇪🇺 EU
- Active substance
- somapacitan
- Company
- Novo Nordisk A/S
- Status
- Authorised
- Therapeutic area
- Growth
- EU approval
- Wed 31 Mar 2021
- Designations
- Additional monitoring
- Application
- EMEA/H/C/005030
- ATC
- H01AC07
- Official record
- www.ema.europa.eu
Indication
Sogroya is indicated for the replacement of endogenous growth hormone (GH) in children aged 3 years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric GHD), and in adults with growth hormone deficiency (adult GHD).
Regulatory milestones
No milestones recorded in the last year.
Follow Sogroya
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.